OncoMatch/Clinical Trials/NCT06663098
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
Is NCT06663098 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Carboplatin for extensive stage small cell lung cancer (es-sclc).
Treatment: Atezolizumab · Carboplatin · Etoposide — The goal of this clinical trial is to learn if a combination of atezolizumab and standard chemotherapy works to treat sensitive Extensive-stage Small Cell Lung Cancer, progressing after first-line of treatment. The main questions it aims to answer are: * Does combination of atezolizumab and standard chemotherapy increase overall survival? * What medical problems do participants have when taking combination of atezolizumab and standard chemotherapy? Participants will: * take atezolizumab and standard chemotherapy every 3 weeks for 4 cycles and than atezolizumab every 3 weeks up to 18 cycles. * visit the clinic once every 3 weeks for checkups and tests * perform Radiological assessments after 6 weeks and then every 12 weeks to determine response to treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV (SCLC)
Extensive-stage Small Cell Lung Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Disease progression at least 60 days after the completion of first-line chemotherapy consisting of at least 4 cycles of platinum-etoposide plus either atezolizumab or durvalumab and have not received any other treatment (except for immunotherapy as maintenance treatment)
Must have received: anti-PD-L1 therapy (atezolizumab, durvalumab) — first-line
first-line chemotherapy consisting of at least 4 cycles of platinum-etoposide plus either atezolizumab or durvalumab
Cannot have received: chemotherapy other than platinum-etoposide
First-line chemotherapy other than platinum-etoposide
Cannot have received: more than 1 line of prior treatment
More than 1 line of prior treatment for ES-SCLC
Lab requirements
Blood counts
ANC ≥1500/mm3; Platelet count ≥ 100 x 10^9/L (≥100,000/μL) without transfusion; Hemoglobin ≥ 90 g/L (≥ 9 g/dL); patients may be transfused to meet this criterion
Kidney function
Creatinine < 1.5x ULN or estimated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault) for patients with creatinine above institutional limits
Liver function
Total bilirubin < 1.5x ULN; ALT or AST < 2.5x ULN (< 5x if due to liver metastases)
Normal baseline laboratory values as specified below: * Absolute neutrophil count (ANC) ≥1500/mm3 * Platelet count ≥ 100 x 109/L (≥100,000/μL) without transfusion * Hemoglobin ≥ 90 g/L (≥ 9 g/dL); patients may be transfused to meet this criterion. * Total bilirubin < 1.5x the institutional upper limit of normal (ULN) * Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5x the institutional ULN (< 5x if liver function test elevations are due to liver metastases) * Creatinine < 1.5x institutional ULN or estimated creatinine clearance using the Cockcroft-Gault formula ≥ 30 mL/minute for patients with creatinine levels above institutional limits
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify